Breakthrough In Two Pages: US FDA Offers Pharma Preliminary Advice
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is offering preliminary advice on whether a drug in development could warrant a breakthrough designation, another seemingly lesser-known attempt at limiting the burden of reviewing formal requests to be part of the program.